Format

Send to

Choose Destination
Drug Saf. 2016 Jul;39(7):627-45. doi: 10.1007/s40264-016-0416-y.

Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence.

Author information

1
Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK. julia.sinclair@soton.ac.uk.
2
University Department of Psychiatry, Academic Centre, College Keep, 4-12 Terminus Terrace, Southampton, SO14 3DT, UK. julia.sinclair@soton.ac.uk.
3
Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
4
Academic Foundation Programme, Wessex Deanery, Winchester, UK.
5
University of Cape Town, Cape Town, South Africa.

Abstract

Alcohol use disorders (AUD) cause significant morbidity and mortality worldwide, but pharmacological treatments for them are underused, despite evidence of efficacy. Acamprosate, naltrexone, nalmefene and disulfiram are all approved in one or more region for the treatment of AUD. Baclofen currently has a temporary indication in France. Safety considerations for using psychopharmacological treatments in this patient group include the impact of concurrent alcohol consumption at high levels; multiple physical comorbidities that may interfere with pharmacological effects, distribution and metabolism; and concomitant medication for the treatment of comorbid physical and psychiatric conditions. The five drugs, including an extended-release injectable suspension of naltrexone, have different safety profiles that need to be balanced with the treatment objective (initiation or continuation of abstinence, or reduction of drinking), individual patient preferences and comorbid conditions. Appropriate treatment will be based on the unique risk-benefit profile in each case.

PMID:
27023898
DOI:
10.1007/s40264-016-0416-y
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center